BSE: SANOFI - Sanofi India Limited

Rentabilität für sechs Monate: -13.79%
Dividendenrendite: +1.71%

Aktionsplan Sanofi India Limited

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Sanofi India Limited

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors.

weitere details
It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

ISIN INE058A01010
Industry Pharmaceuticals
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 1.71
Дивиденд ао 68.21
Сайт https://www.sanofiindialtd.com
Цена ао 5991.15
Preisänderung pro Tag: -2.67% (5991.15)
Preisänderung pro Woche: +2.25% (5702.95)
Preisänderung pro Monat: +15.25% (5059.65)
Preisänderung über 3 Monate: -4.34% (6095.85)
Preisänderung über sechs Monate: -13.79% (6764.2)
Preisänderung pro Jahr: -28.17% (8118.25)
Preisänderung über 3 Jahre: -20.58% (7341.85)
Preisänderung über 5 Jahre: -20.85% (7367.55)
Preisänderung seit Jahresbeginn: -5.23% (6152.95)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 6.55 1
P/BV 18.17 1
P/E 30.59 5
EV/EBITDA 17.69 6
Gesamt: 4.63

Effizienz

Name Bedeutung Grad
ROA, % 35.16 9
ROE, % 59.39 10
Gesamt: 5.83

Dividenden

Name Bedeutung Grad
Div yield, % 1.71 4.28
DSI 0.8571 8.57
Gesamt: 5.02

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0.026 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -8.24 0
Rentabilität Ebitda, % 20.55 4
Rentabilität EPS, % 50.5 7
Gesamt: 3.4
Weitere Details

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
iShares MSCI India Small-Cap ETF 0.16695 0.4625 0.96163
SPDR S&P Emerging Markets Small Cap ETF 0.07114 5.46 3.03583
iShares MSCI Emerging Markets Small-Cap ETF 0.04483 7.67 2.7853
Avantis Emerging Markets Value ETF 0.03441 14.12 4.22231
Avantis Responsible Emerging Markets Equity ETF 0.02777 17.6 3.1719
Vanguard FTSE All-World ex-US Small-Cap ETF 0.02 9.39 3.09932
Avantis Emerging Markets Equity ETF 0.01484 8.77 3.60513
Dimensional Emerging Markets Core Equity 2 ETF 0.0079 15.96 3.34087
Dimensional World ex U.S. Core Equity 2 ETF 0.00469 13.06 3.62488
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund 0.00447 12.46 3.59676
0.0410.53.15

Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Rodolfo Hrosz MD & Director 17.85M 1967 (58 Jahre)
Mr. M. K. Narayanaswamy B.Com.,A.I.C.W.A. Senior Director of Accounting & Taxation N/A 1955 (70 Jahre)
Mr. Sanjay V. Chavan Head of Country Procurement - India N/A 1962 (63 Jahr)
Ms. Surabhi Kaur People & Culture Director N/A
Ms. Renee Amonkar Additional Whole Time Director N/A
Mr. Rachid Ayari CFO & Whole Time Director N/A
Ms. Flovie Martins Head of Corporate Communications & Corporate Social Responsibility
Nakul Verma Senior Director of Public Affairs
Yasmin Shenoy Senior Director of Regulatory Affairs
Mr. N. Suresh Babu Sales & Customer Engagement Head - Diabetes and Senior Director of Diabetes

Adresse: India, Mumbai, Sanofi House - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.sanofiindialtd.com